$FATE
Fate Therapeutics Inc

2022 Q1 Form 10-K Financial Statement

#000095017022002293 Filed on February 28, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021
Revenue $18.41M $17.07M $55.85M
YoY Change 65.27% 7.35% 77.66%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $20.74M $16.94M $57.32M
YoY Change 65.94% 64.27% 69.09%
% of Gross Profit
Research & Development $72.14M $69.52M $215.5M
YoY Change 60.84% 78.34% 71.56%
% of Gross Profit
Depreciation & Amortization $2.761M $2.206M $5.900M
YoY Change 187.9% 156.51% 90.32%
% of Gross Profit
Operating Expenses $92.88M $86.45M $272.8M
YoY Change 61.95% 75.36% 71.04%
Operating Profit -$74.47M -$217.0M
YoY Change 61.15% 69.41%
Interest Expense $8.777M $761.0K $0.00
YoY Change 683.66% -103.86%
% of Operating Profit
Other Income/Expense, Net $8.777M $4.843M
YoY Change 682.96% -110.69%
Pretax Income -$65.69M -$68.62M -$212.2M
YoY Change 45.69% 29.21% 22.35%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$65.69M -$68.62M -$212.2M
YoY Change 45.69% 29.21% 22.36%
Net Earnings / Revenue -356.74% -402.02% -379.89%
Basic Earnings Per Share -$0.68 -$2.24
Diluted Earnings Per Share -$681.8K -$716.3K -$2.239M
COMMON SHARES
Basic Shares Outstanding 96.43M 95.49M 94.75M
Diluted Shares Outstanding 96.34M 94.75M

Balance Sheet

Concept 2022 Q1 2021 Q4 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $573.8M $615.9M $615.9M
YoY Change -27.38% 27.54% 27.54%
Cash & Equivalents $64.74M $133.6M $133.6M
Short-Term Investments $509.0M $482.3M $482.3M
Other Short-Term Assets $11.45M $8.826M $8.826M
YoY Change 59.07% 49.59% 49.59%
Inventory
Prepaid Expenses
Receivables $13.85M $8.676M $8.676M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $599.1M $633.4M $633.4M
YoY Change -25.52% 28.14% 28.14%
LONG-TERM ASSETS
Property, Plant & Equipment $97.86M $91.53M $162.2M
YoY Change -15.05% 183.3% 63.23%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $67.94M $100.7M $100.7M
YoY Change -30.88%
Other Assets $33.00K $33.00K $15.26M
YoY Change -99.78% 266.67% 0.39%
Total Long-Term Assets $259.3M $288.0M $288.0M
YoY Change 7.29% 124.8% 124.68%
TOTAL ASSETS
Total Short-Term Assets $599.1M $633.4M $633.4M
Total Long-Term Assets $259.3M $288.0M $288.0M
Total Assets $858.4M $921.5M $921.5M
YoY Change -17.94% 48.04% 48.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.44M $8.612M $8.612M
YoY Change 27.16% 37.07% 36.7%
Accrued Expenses $35.11M $42.41M $47.99M
YoY Change 67.74% 172.5% 153.91%
Deferred Revenue $22.58M $21.48M
YoY Change 1.6%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $77.91M $81.28M $81.28M
YoY Change -17.64% -5.0% -5.04%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $147.1M $161.3M $161.3M
YoY Change -8.81% 5.86% 5.86%
Total Long-Term Liabilities $147.1M $161.3M $161.3M
YoY Change -8.81% 5.86% 5.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $77.91M $81.28M $81.28M
Total Long-Term Liabilities $147.1M $161.3M $161.3M
Total Liabilities $225.0M $242.6M $242.6M
YoY Change -12.08% 1.94% 1.94%
SHAREHOLDERS EQUITY
Retained Earnings -$834.8M -$769.1M
YoY Change 38.09%
Common Stock $97.00K $96.00K
YoY Change 9.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $633.4M $678.8M $678.8M
YoY Change
Total Liabilities & Shareholders Equity $858.4M $921.5M $921.5M
YoY Change -17.94% 48.04% 48.02%

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021
OPERATING ACTIVITIES
Net Income -$65.69M -$68.62M -$212.2M
YoY Change 45.69% 29.21% 22.36%
Depreciation, Depletion And Amortization $2.761M $2.206M $5.900M
YoY Change 187.9% 156.51% 90.32%
Cash From Operating Activities -$64.61M -$70.29M -$162.9M
YoY Change 138.46% 240.24% 315.18%
INVESTING ACTIVITIES
Capital Expenditures $10.08M -$18.37M $50.70M
YoY Change 153.3% 709.21% 928.06%
Acquisitions
YoY Change
Other Investing Activities $3.058M $89.65M -$273.3M
YoY Change -100.65% -154.75% 75.05%
Cash From Investing Activities -$7.026M $71.28M -$324.0M
YoY Change -98.51% -142.93% 101.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $411.7M
YoY Change 118.1%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.797M 3.418M 453.1M
YoY Change -99.36% -30.39% 60.21%
NET CHANGE
Cash From Operating Activities -64.61M -70.29M -162.9M
Cash From Investing Activities -7.026M 71.28M -324.0M
Cash From Financing Activities 2.797M 3.418M 453.1M
Net Change In Cash -68.84M 4.403M -33.76M
YoY Change 12.98% -102.42% -140.91%
FREE CASH FLOW
Cash From Operating Activities -$64.61M -$70.29M -$162.9M
Capital Expenditures $10.08M -$18.37M $50.70M
Free Cash Flow -$74.70M -$51.92M -$213.6M
YoY Change 140.36% 182.35% 383.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2019 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
CY2020 us-gaap Interest Paid Net
InterestPaidNet
CY2021 us-gaap Interest Paid Net
InterestPaidNet
CY2019 fate Proceeds From Cirm Award
ProceedsFromCIRMAward
CY2019Q4 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2019 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#LicenseMember
CY2020Q4 us-gaap Long Term Investments
LongTermInvestments
CY2019 fate Proceeds From Issuance Of Pre Funded Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfPreFundedWarrantsNetOfIssuanceCosts
CY2021 fate Proceeds From Cirm Award
ProceedsFromCIRMAward
CY2020 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
CY2019 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
CY2020 fate Proceeds From Issuance Of Pre Funded Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfPreFundedWarrantsNetOfIssuanceCosts
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001434316
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2020 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
CY2021Q4 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
CY2020 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019 fate Proceeds From Issuance Of Common Stock In Connection With Collaboration Agreement
ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement
CY2019 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
CY2021 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
CY2018 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2019 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
CY2020Q4 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2021 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
CY2020 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#LicenseMember
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#LicenseMember
CY2020 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
CY2021 fate Proceeds From Issuance Of Common Stock In Connection With Collaboration Agreement
ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-36076
CY2021 dei Entity Registrant Name
EntityRegistrantName
FATE THERAPEUTICS, INC.
CY2021 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2021 dei Trading Symbol
TradingSymbol
FATE
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
65-1311552
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
12278 Scripps Summit Drive
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92131
CY2021 dei City Area Code
CityAreaCode
858
CY2021 dei Local Phone Number
LocalPhoneNumber
875-1800
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
false
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
6960000000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
96427693
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
133583000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
167347000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8676000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5515000
CY2021Q4 fate Short Term Investments And Related Maturity Receivables
ShortTermInvestmentsAndRelatedMaturityReceivables
482327000
CY2020Q4 fate Short Term Investments And Related Maturity Receivables
ShortTermInvestmentsAndRelatedMaturityReceivables
315569000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8826000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5892000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
633412000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
494323000
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
100664000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
91529000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32308000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
70720000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
67084000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
15227000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
15227000
CY2021Q4 us-gaap Contract With Customer Asset Net Noncurrent
ContractWithCustomerAssetNetNoncurrent
9870000
CY2020Q4 us-gaap Contract With Customer Asset Net Noncurrent
ContractWithCustomerAssetNetNoncurrent
13506000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
9000
CY2021Q4 us-gaap Assets
Assets
921455000
CY2020Q4 us-gaap Assets
Assets
622457000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8612000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6283000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
42412000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15564000
CY2021Q4 fate Cirm Award Liability Current
CIRMAwardLiabilityCurrent
3200000
CY2020Q4 fate Cirm Award Liability Current
CIRMAwardLiabilityCurrent
3200000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
21483000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
21144000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5577000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3355000
CY2021Q4 fate Stock Price Appreciation Milestones Liabilities Current
StockPriceAppreciationMilestonesLiabilitiesCurrent
0
CY2020Q4 fate Stock Price Appreciation Milestones Liabilities Current
StockPriceAppreciationMilestonesLiabilitiesCurrent
36018000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
81284000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
85564000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
27124000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
46021000
CY2021Q4 fate Cirm Award Liability Noncurrent
CIRMAwardLiabilityNoncurrent
800000
CY2020Q4 fate Cirm Award Liability Noncurrent
CIRMAwardLiabilityNoncurrent
800000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
109241000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
93943000
CY2021Q4 fate Stock Price Appreciation Milestones Liabilities Non Current
StockPriceAppreciationMilestonesLiabilitiesNonCurrent
24168000
CY2020Q4 fate Stock Price Appreciation Milestones Liabilities Non Current
StockPriceAppreciationMilestonesLiabilitiesNonCurrent
11684000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
3000
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
3000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
95726962
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
95726962
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
87722237
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
87722237
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
96000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
88000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1448584000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
941216000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-762000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
70000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-769083000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-556932000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
678838000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
384445000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
921455000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
622457000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
55846000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31434000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10680000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
215519000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
125623000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
87770000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
57321000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
33896000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23637000
CY2021 us-gaap Operating Expenses
OperatingExpenses
272840000
CY2020 us-gaap Operating Expenses
OperatingExpenses
159519000
CY2019 us-gaap Operating Expenses
OperatingExpenses
111407000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-216994000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-128085000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-100727000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
1309000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
2400000
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
4330000
CY2021 us-gaap Interest Expense
InterestExpense
0
CY2020 us-gaap Interest Expense
InterestExpense
0
CY2019 us-gaap Interest Expense
InterestExpense
1752000
CY2021 fate Increase Decrease In Fair Value Of Stock Price Appreciation Milestones
IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
-3534000
CY2020 fate Increase Decrease In Fair Value Of Stock Price Appreciation Milestones
IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
47702000
CY2019 fate Increase Decrease In Fair Value Of Stock Price Appreciation Milestones
IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
0
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4843000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-45302000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2578000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-212151000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-173387000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-98149000
CY2021 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-832000
CY2020 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
48000
CY2019 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
24000
CY2021 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-212983000
CY2020 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-173339000
CY2019 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-98125000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.24
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.10
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.44
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
94747311
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
82385319
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
68190741
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
160469000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2596000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17410000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
162406000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
24000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-98149000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
244756000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9582000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
30753000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
188784000
CY2020 fate Common Stock Issued During Period Value Private Placement
CommonStockIssuedDuringPeriodValuePrivatePlacement
49975000
CY2020 fate Stock Issued During Period Value To Collaborative Partner
StockIssuedDuringPeriodValueToCollaborativePartner
33934000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
48000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-173387000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
384445000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
20730000
CY2021 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
1000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
54364000
CY2021 fate Public Offering Of Common Stock And Issuance Of Pre Funded Warrants
PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants
432281000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-832000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-212151000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
678838000
CY2021 us-gaap Profit Loss
ProfitLoss
-212151000
CY2020 us-gaap Profit Loss
ProfitLoss
-173387000
CY2019 us-gaap Profit Loss
ProfitLoss
-98149000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5850000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3087000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2193000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
54364000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
30753000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17410000
CY2019 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
115000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-5067000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1676000
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
478000
CY2021 us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
3995000
CY2020 us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
3110000
CY2019 us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
620000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-18559000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
60603000
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-8526000
CY2021 fate Increase Decrease In Fair Value Of Stock Price Appreciation Milestones
IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
-3534000
CY2020 fate Increase Decrease In Fair Value Of Stock Price Appreciation Milestones
IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
47702000
CY2019 fate Increase Decrease In Fair Value Of Stock Price Appreciation Milestones
IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
0
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3160000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5515000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-500000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3052000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
13582000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1911000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5907000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1554000
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4277000
CY2021 fate Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
2403000
CY2020 fate Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
7878000
CY2019 fate Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
774000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-162870000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39229000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-83175000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
50704000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4932000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7395000
CY2021 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
968159000
CY2020 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
277344000
CY2019 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
248858000
CY2021 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
694840000
CY2020 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
121200000
CY2019 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
98800000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-324023000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-161076000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-157453000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
20714000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
9655000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2522000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
411735000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
188784000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
162406000
CY2021 fate Proceeds From Issuance Of Pre Funded Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfPreFundedWarrantsNetOfIssuanceCosts
20680000
CY2020 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
49975000
CY2020 fate Proceeds From Issuance Of Common Stock In Connection With Collaboration Agreement
ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement
33934000
CY2020 fate Proceeds From Cirm Award
ProceedsFromCIRMAward
490000
CY2019 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
15000000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
453129000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
282838000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
149928000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-33764000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
82533000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-90700000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
182574000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
100041000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
190741000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
148810000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
182574000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
100041000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
2291000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
4371000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1486000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
602000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
8600000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
49287000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
13000
CY2021 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
133000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The preparation of the Company’s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to its stock appreciation milestone obligations, contracts containing leases, accrued expenses and the estimated total costs expected to be incurred under the Company’s collaboration agreements. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></p>
CY2021 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
more than 50 percent
CY2021 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
133583000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
167347000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
99814000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
15227000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
15227000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
227000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
148810000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
182574000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
100041000
CY2021Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
15200000
CY2020Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
15200000
CY2019Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
200000
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Concentration of Credit Risk</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments, which potentially subject the Company to a significant concentration of credit risk, consist primarily of cash and cash equivalents and investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits and investments are held.</span>
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25689840
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25807299
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23820487
CY2020 fate Period To Treat Award As Grant If Award Not Treated As Loan
PeriodToTreatAwardAsGrantIfAwardNotTreatedAsLoan
P10Y
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
414126000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
763000
CY2020Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
166916000
CY2020Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
87000
CY2019 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2020 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2021 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2021Q4 us-gaap Share Price
SharePrice
58.51
CY2021Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
108474000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
43403000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
16945000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11095000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
91529000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32308000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5900000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3100000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2200000
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
18358000
CY2020Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
4815000
CY2021Q4 fate Accrued Clinical Trial Related Costs Current
AccruedClinicalTrialRelatedCostsCurrent
12344000
CY2020Q4 fate Accrued Clinical Trial Related Costs Current
AccruedClinicalTrialRelatedCostsCurrent
5244000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
11710000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5505000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
42412000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15564000
CY2019 us-gaap Interest Expense Debt
InterestExpenseDebt
1800000
CY2021 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
These leases have terms varying from one to approximately sixteen years, with renewal options of up to ten years
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P12Y3M18D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0694
CY2021 us-gaap Straight Line Rent Adjustments
StraightLineRentAdjustments
15354000
CY2020 us-gaap Straight Line Rent Adjustments
StraightLineRentAdjustments
12076000
CY2019 us-gaap Straight Line Rent Adjustments
StraightLineRentAdjustments
3781000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
1660000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
2245000
CY2019 us-gaap Variable Lease Cost
VariableLeaseCost
2330000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
17014000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
14321000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
6111000
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2020 us-gaap Short Term Lease Cost
ShortTermLeaseCost
1200000
CY2019 us-gaap Short Term Lease Cost
ShortTermLeaseCost
1100000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
14970000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
14498000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
14836000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
15087000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
15540000
CY2021Q4 fate Lessee Operating Lease Liability Payments Due Year Six
LesseeOperatingLeaseLiabilityPaymentsDueYearSix
16006000
CY2021Q4 fate Lessee Operating Lease Liability Payments Due After Year Six
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix
101635000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
192573000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
77755000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
114818000
CY2021 us-gaap Dividends
Dividends
0
CY2021 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
1997377
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
54364000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
30753000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17410000
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
30631786
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
29704815
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-44551000
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-36411000
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-20611000
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-6966000
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1296000
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2088000
CY2021 fate Income Tax Reconciliation Nondeductible Compensation
IncomeTaxReconciliationNondeductibleCompensation
10202000
CY2020 fate Income Tax Reconciliation Nondeductible Compensation
IncomeTaxReconciliationNondeductibleCompensation
75000
CY2019 fate Income Tax Reconciliation Nondeductible Compensation
IncomeTaxReconciliationNondeductibleCompensation
86000
CY2021 fate Income Tax Reconciliation Permanent Tax Differences
IncomeTaxReconciliationPermanentTaxDifferences
-686000
CY2020 fate Income Tax Reconciliation Permanent Tax Differences
IncomeTaxReconciliationPermanentTaxDifferences
-240000
CY2019 fate Income Tax Reconciliation Permanent Tax Differences
IncomeTaxReconciliationPermanentTaxDifferences
89000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-35852000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-6073000
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
359000
CY2021 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
12140000
CY2020 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
7177000
CY2019 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
7285000
CY2021 fate Income Tax Reconciliation Reserve For Uncertain Tax Positions
IncomeTaxReconciliationReserveForUncertainTaxPositions
7192000
CY2020 fate Income Tax Reconciliation Reserve For Uncertain Tax Positions
IncomeTaxReconciliationReserveForUncertainTaxPositions
1555000
CY2019 fate Income Tax Reconciliation Reserve For Uncertain Tax Positions
IncomeTaxReconciliationReserveForUncertainTaxPositions
2163000
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
84000
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
70000
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
77000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
82717000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
49497000
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
27210000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q4 fate Deferred Tax Assets Section59e Amortization
DeferredTaxAssetsSection59eAmortization
95172000
CY2020Q4 fate Deferred Tax Assets Section59e Amortization
DeferredTaxAssetsSection59eAmortization
48195000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
62913000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
41213000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
35387000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
23488000
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
6985000
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
2615000
CY2021Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
8706000
CY2020Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
11915000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
8710000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4307000
CY2021Q4 fate Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
24112000
CY2020Q4 fate Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
20433000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
6972000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
10208000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
248957000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
162374000
CY2021Q4 fate Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
7323000
CY2020Q4 fate Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
4220000
CY2021Q4 fate Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
14851000
CY2020Q4 fate Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
14088000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
22174000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
18308000
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
226783000
CY2020Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
144066000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
226783000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
144066000
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
226800000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
144100000
CY2021 fate Cumulative Change In Ownership Percentage
CumulativeChangeInOwnershipPercentage
0.50
CY2021 fate Period For Cumulative Change In Ownership
PeriodForCumulativeChangeInOwnership
P3Y
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
19779000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
16822000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
13547000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
17557000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1837000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
3196000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
1120000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
79000
CY2021 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
81000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
37255000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
19779000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
16822000
CY2021Q4 fate Unrecognized Tax Benefits Resulting In Net Operating Loss And Tax Credit Carryforward
UnrecognizedTaxBenefitsResultingInNetOperatingLossAndTaxCreditCarryforward
0
CY2021Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2009Q1 fate Defined Contribution Plan Minimum Age Of Employee
DefinedContributionPlanMinimumAgeOfEmployee
P21Y
CY2021 fate Percentage Of Discretionary Contributions Description
PercentageOfDiscretionaryContributionsDescription
The Company makes discretionary contributions to the 401(k) Plan equal to 100 percent of each employee’s pretax contributions up to 20 percent of the IRS Standard Limit.
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0
CY2021 fate Minimum Annual Payments To Maintain Licenses
MinimumAnnualPaymentsToMaintainLicenses
400000
CY2021 dei Auditor Name
AuditorName
Ernst & Young, LLP
CY2021 dei Auditor Location
AuditorLocation
San Diego, CA
CY2021 dei Auditor Firm
AuditorFirmId
42

Files In Submission

Name View Source Status
0000950170-22-002293-index-headers.html Edgar Link pending
0000950170-22-002293-index.html Edgar Link pending
0000950170-22-002293.txt Edgar Link pending
0000950170-22-002293-xbrl.zip Edgar Link pending
fate-20211231.htm Edgar Link pending
fate-20211231.xsd Edgar Link pending
fate-20211231_cal.xml Edgar Link unprocessable
fate-20211231_def.xml Edgar Link unprocessable
fate-20211231_htm.xml Edgar Link completed
fate-20211231_lab.xml Edgar Link unprocessable
fate-20211231_pre.xml Edgar Link unprocessable
fate-ex10_40.htm Edgar Link pending
fate-ex23_1.htm Edgar Link pending
fate-ex31_1.htm Edgar Link pending
fate-ex31_2.htm Edgar Link pending
fate-ex32_1.htm Edgar Link pending
fate-ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img141040381_0.jpg Edgar Link pending
img141040381_1.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending